Authors: Eva Šťastná; Hana Višňová Authors place of work: IVF CUBE, Praha Published in the journal: Ceska Gynekol 2025; 90(6): 435-441 Category: Původní práce doi: https://doi.org/10.48095/cccg2025435
Objective: Despite advancements in assisted reproduction, the cause of up to 50% of cases of idiopathic fertility disorders remains unclear. The immune system, particularly the interaction between human leukocyte antigen-C (HLA-C) molecules on the trophoblast and killer-cell immunoglobulin-like receptors (KIR) on uterine natural killer (NK) cells, plays a crucial role in implantation and placental development. The aim of this analysis was to evaluate our experience with testing KIR/HLA-C compatibility and its potential role in personalizing infertility treatment. Methods: This is an interventional study examining the success of therapy in 23 couples who underwent infertility treatment with donated gametes between 1/2023 and 12/2024, with additional consideration of KIR/HLA-C compatibility between the recipient and the donor. For better homogeneity of the sample, patients in the intervention group were divided into two subgroups. The first subgroup consisted of 14 couples undergoing their first therapy with donated gametes. The second subgroup consisted of 9 couples with a history of repeated unsuccessful embryo transfers from donated gametes. A control group of 320 single embryo transfers with donated gametes from couples treated using standard methods between 1/2023 and 12/2024 was used for comparison. Results: In both intervention subgroups, success rates were comparable. Clinical pregnancy was achieved in 62.5% and 63.6%, resp., which exceeded the average success rate of 55.2% in the control group. Conclusion: The high number of achieved clinical pregnancies in a prognostically unfavorable group, burdened by repeated unsuccessful embryo transfers, appears to be a therapeutic success. It is important to bear in mind the low number of evaluated transfers; however, this result suggests that testing KIR/HLA-C compatibility between the recipient and the donor and taking it into account when selecting a donor may significantly increase the success of therapy in indicated cases.
immunogenetics – infertility – killer-cell immunoglobulin-like receptors – human leukocyte antigen-C – uterine natural killer cells – repeated implantation failure – granulocyte-colony stimulating factor
1. Moffett A, Colucci F. Uterine NK cells: active regulators at the maternal-fetal interface. J Clin Invest 2014; 124 (5): 1872–1879. doi: 10.1172/JCI68107.
2. Koopman LA, Kopcow HD, Rybalov B et al. Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J Exp Med 2003; 198 (8): 1201–1212. doi: 10.1084/jem.20030305.
3. Hanna J, Goldman-Wohl D, Hamani Y et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006; 12 (10): 1065–1074. doi: 10.1038/nm1452.
4. Hiby SE, Walker JJ, O’Shaughnessy KM et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 2004; 200 (8): 957–965. doi: 10.1084/jem.20041214.
5. Hiby SE, Apps R, Sharkey AM et al. Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. J Clin Invest 2010; 120 (11): 4102–4110. doi: 10.1172/JCI43998.
6. Brosens I, Pijnenborg R, Vercruysse L et al. The „Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol 2011; 204 (3): 193–201. doi: 10.1016/j.ajog.2010.08.009.
7. Moffett A, Chazara O, Colucci F et al. Variation of maternal KIR and fetal HLA-C genes in reproductive failure: too early for clinical intervention. Hum Reprod Update 2022; 28 (4): 548–582. doi: 10.1093/humupd/dmac006.
8. Colucci F. The role of KIR and HLA interactions in pregnancy complications. Immunogenetics 2017; 69 (8–9): 557–565. doi: 10.1007/s00251-017-1003-9.
9. Grimstad F, Krieg S. Immunogenetic contributions to recurrent pregnancy loss. J Assist Reprod Genet 2016; 33 (7): 833–847. doi: 10.1007/s10815-016-0720-6.
10. Hiby SE, Apps R, Chazara O et al. Maternal KIR in combination with paternal HLA-C2 regulate human birth weight. J Immunol 2014; 192 (11): 5069–5073. doi: 10.4049/jimmunol.1400577.
11. Bos M, Colucci F. A new look at immunogenetics of pregnancy: maternal major histocompatibility complex class I educates uterine natural killer cells. Int J. Mol Sci 2024; 25 (16): 8869. doi: 10.3390/ijms25168869.
12. Cruz M, Alecsandru D, García-Velasco JA et al. Use of granulocyte colony-stimulating factor in ART treatment does not increase the risk of adverse perinatal outcomes. Reprod Biol Online 2019; 39 (6): 97–980. doi: 10.1016/j.rbmo.2019.09.008.
13. Alecsandru D, Barrio A, Garrido N et al. Parental human leukocyte antigen-C allotypes are predictive of live birth rate and risk of poor placentation in assisted reproductive treatment. Fertil Steril 2020; 114 (4): 809–817. doi: 10.1016/ j.fertnstert.2020.05.008.
14. Würfel W. Treatment with granulocyte colony-stimulating factor in patients with repetitive implantation failures and/or recurrent spontaneous abortions. J Reprod Immunol 2015; 108 : 123–135. doi: 10.1016/j.jri.2015.01. 010.
15. Rahmati M, Petitbarat M, Dubanchet S et al. Granulocyte-colony stimulating factor related pathways tested on an endometrial ex-vivo model. PLoS One 2014; 9 (10): e102286. doi: 10.1371/journal.pone.0102286.
16. Cozzolino M, Pellegrini L, Tartaglia S et al. Subcutaneous G-CSF administration improves IVF outcomes in patients with recurrent implantation failure presenting a KIR/HLA-C mismatch. J Reprod Immunol 2024; 165 : 104310. doi: 10.1016/j.jri.2024.104310.
17. Pavlova Y, Kolesar L, Striz I et al. Distribution of KIR genes in the Czech population. Int J Immunogenet 2008; 35 (1): 57–61. doi: 10.1111/j.1744-313X.2007.00737.x.
18. Díaz-Hernández I, Alecsandru D, García-Velasco JA et al. Uterine natural killer cells: from foe to friend in reproduction. Hum Reprod Update 2021; 27 (4): 720–746. doi: 10.1093/humupd/ dmaa062.
19. Maternal KIR and Fetal HLA Influence Reproductive Success in ART-oocyte Donor. NCT05606679. Observational study, IVI Madrid. 2024 [online]. Available from: https: //trial.medpath.com/clinical-trial/3f0f4d02cf03a7d8/nct05606679-maternal-kir-fetal-hla-influence-reproductive-success.
20. Lundin K, Bentzen JG, Bozdag G et al. Good practice recommendations on add-ons in reproductive medicine. Hum Reprod 2023; 38 (11): 12062–2104. doi: 10.1093/humrep/dead184.
21. Fu LL, Xu Y, Yan J et al. Efficacy of granulocyte colony-stimulating factor for infertility undergoing IVF: a systematic review and meta-analysis. Reprod Biol Endocrinol 2023; 21 (1): 34. doi: 10.1186/s12958-023-01063-z.
22. Hou Z, Jiang F, Yang J et al. What is the impact of granulocyte colony-stimulating factor (G-CSF) in subcutaneous injection or intrauterine infusion and during both the fresh and frozen embryo transfer cycles on recurrent implantation failure: a systematic review and meta-analysis. Reprod Biol Endocrinol 2021; 19 (1): 125. doi: 10.1186/s12958-021-00810-4.
23. Jiang Y, Zhao Q, Zhang Y et al. Treatment of G-CSF in unexplained, repeated implantation failure: a systematic review and meta-analysis. J Gynecol Obstet Hum Reprod 2020 : 101866. doi: 10.1016/j.jogoh.2020.101866.
24. Su Q, Pan Z, Yin R et al. The value of G-CSF in women experienced at least one implantation failure: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2024; 15 : 1370114. doi: 10.3389/fendo.2024.1370114.
25. Santjohanser C, Knieper C, Franz C et al. Granulocyte-colony stimulating factor as treatment option in patients with recurrent miscarriage. Arch Immunol Ther Exp 2013; 61 (2): 159–164. doi: 10.1007/s00005-012-0212-z.
Doručeno/Submitted: 15. 6. 2025
Přijato/Accepted: 16. 9. 2025
MUDr. Eva Šťastná
IVF CUBE
Evropská 423/178
160 00 Praha 6
e.stastna@ivf-cube.eu
Zvyšte si kvalifikaci online z pohodlí domova
Nemáte účet? Registrujte se
Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.
